References

1.     International Commission on Radiological Protection, editor. Radiation dose to patients from radiopharmaceuticals: a report of a task group of committees 2 and 3 of the International Commission on Radiological Protection; adopted by the commission in November 1992; [including addendum 1]. Oxford: Pergamon Press; 1994. 377 p. (ICRP publication Radiation protection, addendum 1).

2.     ICRP. Radiation Dose to Patients from Radiopharmaceuticals - Addendum 3 to ICRP Publication 53. Annals of the ICRP. 2008;38.

3.     Mattsson S, Johansson L, Leide Svegborn S, Liniecki J, Noßke D, Riklund KÅ, et al. ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals: a Compendium of Current Information Related to Frequently Used Substances. Ann ICRP. 2015 Jul;44(2_suppl):7–321.

4.     Mc Ardle B, Dowsley TF, Cocker MS, Ohira H, deKemp RA, DaSilva J, et al. Cardiac PET: Metabolic and Functional Imaging of the Myocardium. Seminars in Nuclear Medicine. 2013 Nov;43(6):434–48.

5.     Agostini D, Ben-Haim S, Rouzet F, Songy B, Giordano A, Gimelli A, et al. Performance of cardiac cadmium-zinc-telluride gamma camera imaging in coronary artery disease: a review from the cardiovascular committee of the European Association of Nuclear Medicine (EANM). Eur J Nucl Med Mol Imaging. 2016 Dec;43(13):2423–32.

6.     Agostini D, Roule V, Nganoa C, Roth N, Baavour R, Parienti JJ, et al. First validation of myocardial flow reserve assessed by dynamic 99mTc-sestamibi CZT-SPECT camera: head to head comparison with 15O-water PET and fractional flow reserve in patients with suspected coronary artery disease. The WATERDAY study. Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1079–90.

7.     Machac J. Cardiac positron emission tomography imaging. Seminars in Nuclear Medicine. 2005 Jan;35(1):17–36.

8.     Di Carli MF, Hachamovitch R. New Technology for Noninvasive Evaluation of Coronary Artery Disease. Circulation. 2007 Mar 20;115(11):1464–80.

9.     Dorbala S, Vangala D, Sampson U, Limaye A, Kwong R, Di Carli MF. Value of vasodilator left ventricular ejection fraction reserve in evaluating the magnitude of myocardium at risk and the extent of angiographic coronary artery disease: a 82Rb PET/CT study. J Nucl Med. 2007 Mar;48(3):349–58.

10.     Lertsburapa K, Ahlberg AW, Bateman TM, Katten D, Volker L, Cullom SJ, et al. Independent and incremental prognostic value of left ventricular ejection fraction determined by stress gated rubidium 82 PET imaging in patients with known or suspected coronary artery disease. J Nucl Cardiol. 2008 Nov;15(6):745–53.

11.     Le Guludec D, Lautamäki R, Knuuti J, Bax JJ, Bengel FM. Present and future of clinical cardiovascular PET imaging in Europe—a position statement by the European Council of Nuclear Cardiology (ECNC). Eur J Nucl Med Mol Imaging. 2008 Sep;35(9):1709–24.

12.     Andersson M, Johansson L, Minarik D, Leide-Svegborn S, Mattsson S. Effective dose to adult patients from 338 radiopharmaceuticals estimated using ICRP biokinetic data, ICRP/ICRU computational reference phantoms and ICRP 2007 tissue weighting factors. EJNMMI Phys. 2014 Dec;1(1):9.

13.     Mercolli L, Bregenzer C, Diemling M, Mingels C, Rominger A, Sari H, Seibel S, Sohlberg A, Viscione M, Caobelli F. Internal dosimetry study of [82Rb]Cl using a long axial field-of-view PET/CT. Eur J Nucl Med Mol Imaging. 2024 Jun;51(7):1869-1875. doi: 10.1007/s00259-024-06660-7. Epub 2024 Feb 26. PMID: 38407598; PMCID: PMC11139737.

14.     Monroy-Gonzalez AG, Juarez-Orozco LE, Han C, Vedder IR, García DV, Borra R, et al. Software reproducibility of myocardial blood flow and flow reserve quantification in ischemic heart disease: A 13N-ammonia PET study. Journal of Nuclear Cardiology. 2020 Aug;27(4):1225–33.

15.     Munari M, Zucchetta P, Carollo C, Gallo F, De Nardin M, Marzola MC, et al. Confirmatory tests in the diagnosis of brain death: Comparison between SPECT and contrast angiography: Critical Care Medicine. 2005 Sep;33(9):2068–73.

16.     Verberne HJ, Acampa W, Anagnostopoulos C, Ballinger J, Bengel F, De Bondt P, et al. EANM procedural guidelines for radionuclide myocardial perfusion imaging with SPECT and SPECT/CT: 2015 revision. Eur J Nucl Med Mol Imaging. 2015 Nov;42(12):1929–40.

17.     2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014 Oct 1;35(37):2541–619.

18.      Hesse B, Lindhardt TB, Acampa W, Anagnostopoulos C, Ballinger J, Bax JJ, et al. EANM/ESC guidelines for radionuclide imaging of cardiac function. Eur J Nucl Med Mol Imaging. 2008 Apr;35(4):851–85.

19.     Kamp, A., Andersson, M., Leide-Svegborn, S. et al. A revised compartmental model for biokinetics and dosimetry of 2-[18F]FDG. EJNMMI Phys 10, 10 (2023). https://doi.org/10.1186/s40658-023-00528-9

20.     Mattson S, International Commission on Radiological Protection, editors. Radiation dose to patients from radiopharmaceuticals: a compendium of current information related to frequently used substances. London: SAGE; 2015. 321 p. (Annals of the ICRP).

21.     Surasi DS, Bhambhvani P, Baldwin JA, Almodovar SE, O’Malley JP. 18F-FDG PET and PET/CT Patient Preparation: A Review of the Literature. Journal of Nuclear Medicine Technology. 2014 Mar 1;42(1):5–13.

22.     Hussain K, Shetty M. Cardiac Sarcoidosis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Apr 15]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK578192/

23.     Trivieri MG, Spagnolo P, Birnie D, Liu P, Drake W, Kovacic JC, et al. Challenges in Cardiac and Pulmonary Sarcoidosis. Journal of the American College of Cardiology. 2020 Oct;76(16):1878–901.

24.     Ezzeddine FM, Kapa S, Rosenbaum A, Blauwet L, Deshmukh AJ, AbouEzzeddine OF, et al. Electrogram‐guided endomyocardial biopsy yield in patients with suspected cardiac sarcoidosis and relation to outcomes. Cardiovasc electrophysiol. 2021 Sep;32(9):2486–95.

25.     Bhatia K, Ramirez R, Narasimhan B, Walsh S, Sud K, Uberoi G, et al. Prognostic role of positron emission tomography in patients with known or suspected cardiac sarcoidosis. a systematic review and meta-analysis. European Heart Journal. 2020 Nov 1;41(Supplement_2):ehaa946.0286.

26.     Bekki M, Tahara N, Tahara A, Sugiyama Y, Maeda-Ogata S, Honda A, et al. Localization of myocardial FDG uptake for prognostic risk stratification in corticosteroid-naïve cardiac sarcoidosis. Journal of Nuclear Cardiology. 2022 Oct;29(5):2132–44.

27.     Taegtmeyer H. Tracing cardiac metabolism in vivo: one substrate at a time. J Nucl Med. 2010 May 1;51 Suppl 1(0 1):80S-87S.

28.     Wisneski JA, Gertz EW, Neese RA, Mayr M. Myocardial metabolism of free fatty acids. Studies with 14C-labeled substrates in humans. J Clin Invest. 1987 Feb;79(2):359–66.

29.     Slart RHJA, Glaudemans AWJM, Lancellotti P, Hyafil F, Blankstein R, Schwartz RG, Jaber WA, Russell R, Gimelli A, Rouzet F, Hacker M, Gheysens O, Plein S, Miller EJ, Dorbala S, Donal E; Document Reading Group. A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology. J Nucl Cardiol. 2018 Feb;25(1):298-319. doi: 10.1007/s12350-017-1043-4. PMID: 29043557.

30.     Ozutemiz C, Koksel Y, Froelich JW, Rubin N, Bhargava M, Roukuz H, et al. COMPARISON OF THE EFFECT OF THREE DIFFERENT DIETARY MODIFICATIONS ON MYOCARDIAL SUPPRESSION IN 18F-FDG PET/CT EVALUATION OF PATIENTS FOR SUSPECTED CARDIAC SARCOIDOSIS. J Nucl Med. 2021 Mar 26;62(12):1759–67.

31.     Dilsizian V, Bacharach SL, Beanlands RS, Bergmann SR, Delbeke D, Dorbala S, et al. ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures. Journal of Nuclear Cardiology. 2016 Oct;23(5):1187–226.

32.     Pepys MB, Dyck RF, de Beer FC, Skinner M, Cohen AS. Binding of serum amyloid P-component (SAP) by amyloid fibrils. Clin Exp Immunol. 1979 Nov;38(2):284–93.

33.     Suhr OB, Lundgren E, Westermark P. One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition. J Intern Med. 2017 Apr;281(4):337–47.

34.     Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016 Jun 14;133(24):2404–12.

35.     Hutt DF, Gilbertson J, Quigley AM, Wechalekar AD. (99m)Tc-DPD scintigraphy as a novel imaging modality for identification of skeletal muscle amyloid deposition in light-chain amyloidosis. Amyloid. 2016 Jun;23(2):134–5.

36.     Bach-Gansmo T, Wien TN, Løndalen A, Halvorsen E. Myocardial uptake of bone scintigraphic agents associated with increased pulmonary uptake. Clin Physiol Funct Imaging. 2016 May;36(3):237–41.

37.     Falk RH, Comenzo RL, Skinner M. The Systemic Amyloidoses. N Engl J Med. 1997 Sep 25;337(13):898–909.

38.     Perugini E, Guidalotti PL, Salvi F, Cooke RMT, Pettinato C, Riva L, et al. Noninvasive Etiologic Diagnosis of Cardiac Amyloidosis Using 99m Tc-3,3-Diphosphono-1,2-Propanodicarboxylic Acid Scintigraphy. Journal of the American College of Cardiology. 2005 Sep;46(6):1076–84.

39.     Treglia G, Glaudemans AWJM, Bertagna F, Hazenberg BPC, Erba PA, Giubbini R, et al. Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis. Eur J Nucl Med Mol Imaging. 2018 Oct;45(11):1945–55.

40.     Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2—Diagnostic criteria and appropriate utilization. Journal of Nuclear Cardiology. 2020 Apr;27(2):659–73.

41.     Chirumamilla A, Travin MI. Cardiac Applications of 123I-mIBG Imaging. Seminars in Nuclear Medicine. 2011 Sep;41(5):374–87.

42.     Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al. Myocardial Iodine-123 Meta-Iodobenzylguanidine Imaging and Cardiac Events in Heart Failure. Journal of the American College of Cardiology. 2010 May;55(20):2212–21.

43.     Sciammarella MG, Gerson M, Buxton AE, Bartley SC, Doukky R, Merlino DA, et al. ASNC/SNMMI Model Coverage Policy: Myocardial sympathetic innervation imaging: Iodine-123 meta-iodobenzylguanidine (123I-mIBG). Journal of Nuclear Cardiology. 2015 Aug;22(4):804–11.

44.     Travin MI, Henzlova MJ, van Eck-Smit BLF, Jain D, Carrió I, Folks RD, et al. Assessment of 123I-mIBG and 99mTc-tetrofosmin single-photon emission computed tomographic images for the prediction of arrhythmic events in patients with ischemic heart failure: Intermediate severity innervation defects are associated with higher arrhythmic risk. J Nucl Cardiol. 2017 Apr;24(2):377–91.

45.     Orimo S, Yogo M, Nakamura T, Suzuki M, Watanabe H. 123I-meta-iodobenzylguanidine (MIBG) cardiac scintigraphy in α-synucleinopathies. Ageing Research Reviews. 2016 Sep;30:122–33.

46.     Flotats A, Carrió I, Agostini D, Le Guludec D, Marcassa C, Schaffers M, et al. Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging. 2010 Aug;37(9):1802–12.

47.     Tobes MC, Fig LM, Carey J, Geatti O, Sisson JC, Shapiro B. Alterations of iodine-131 MIBG biodistribution in an anephric patient: comparison to normal and impaired renal function. J Nucl Med. 1989 Sep;30(9):1476–82.

48.     Taïeb D, Hicks RJ, Hindié E, Guillet BA, Avram A, Ghedini P, et al. European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2112–37.

49.     Tubben A, Prakken NHJ, Ivashchenko OV, Tingen HSA, Glaudemans AWJM, Noordzij W, Nienhuis HLA, van der Meer P, Slart RHJA. Feasibility of the absolute quantification and left ventricular segmentation of cardiac sympathetic innervation in wild-type transthyretin amyloidosis cardiomyopathy with [123I]-MIBG SPECT/CT: The I-NERVE study. J Nucl Cardiol. 2025 Mar;45:102146. doi: 10.1016/j.nuclcard.2025.102146. Epub 2025 Feb 3. PMID: 39909199.

50.     Gimelli A, Aimo A, Vergaro G, Genovesi D, Santonato V, Kusch A, Emdin M, Marzullo P. Cardiac sympathetic denervation in wild-type transthyretin amyloidosis. Amyloid. 2020 Dec;27(4):237-243. doi: 10.1080/13506129.2020.1769059. Epub 2020 May 22. PMID: 32441155.

51.     Bonetti MG, Ciritella P, Valle G, Perrone E. 99mTc HM-PAO brain perfusion SPECT in brain death. Neuroradiology 1995;37:365–9.

52.     Facco E, Zucchetta P, Munari M, Baratto F, Behr A, Gregianin M, et al. 99mTc-HMPAO SPECT in the diagnosis of brain death. Intensive Care Medicine 1998;24:911–917.

53.     Banzo J, Razola P, Araíz JJ, Larraga J, Tardín L, Andrés A, et al. El estudio gammagráfico de perfusión cerebral como prueba de confirmación de muerte encefálica en el proceso de donación de órganos para trasplante. Revista Española de Medicina Nuclear e Imagen Molecular. 2012 Sep;31(5):278–85.

54.     Zaknun JJ, Bal C, Maes A, Tepmongkol S, Vazquez S, Dupont P, et al. Comparative analysis of MR imaging, Ictal SPECT and EEG in temporal lobe epilepsy: a prospective IAEA multi-center study. Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):107–15.

55.     Patil S, Biassoni L, Borgwardt L. Nuclear Medicine in Pediatric Neurology and Neurosurgery: Epilepsy and Brain Tumors. Seminars in Nuclear Medicine. 2007 Sep;37(5):357–81.

56.     Jones AL, Cascino GD. Evidence on Use of Neuroimaging for Surgical Treatment of Temporal Lobe Epilepsy: A Systematic Review. JAMA Neurol. 2016 Apr 1;73(4):464.

57.     Latchaw RE, Yonas H, Hunter GJ, Yuh WTC, Ueda T, Sorensen AG, et al. Guidelines and Recommendations for Perfusion Imaging in Cerebral Ischemia: A Scientific Statement for Healthcare Professionals by the Writing Group on Perfusion Imaging, From the Council on Cardiovascular Radiology of the American Heart Association. Stroke. 2003 Apr;34(4):1084–104.

58.     Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, Banning AP, Budaj A, Buechel RR, Chiariello GA, Chieffo A, Christodorescu RM, Deaton C, Doenst T, Jones HW, Kunadian V, Mehilli J, Milojevic M, Piek JJ, Pugliese F, Rubboli A, Semb AG, Senior R, Berg JM Ten, Belle E Van, Craenenbroeck EM Van, Vidal-Perez R, Winther S. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J 2024;45: 3415–3537 doi: 10.1093/eurheartj/ehae177.

59.     Gallini C, Tutino F, Martone R, Ciaccio A, Costanzo EN, Taborchi G, et al. Semi-quantitative indices of cardiac uptake in patients with suspected cardiac amyloidosis undergoing 99mTc-HMDP scintigraphy. J Nucl Cardiol. 2021;28:90–9.DOI: 10.1007/s12350-019-01643-w. 

60.     GE Healthcare. Adreview FI Sept 2013 Approval Implementation [Internet]. 2013. Available from: https://www.gehealthcare.de/-/jssmedia/global/dach/files/pdx/adreviewfisept2013apprimpl.pdf